BiondVax

BiondVax

BiondVax

BiondVax (NASDAQ: $BVXV) is developing a Universal Flu Vaccine providing multi-season, multi-strain protection against seasonal & pandemic influenza.
Type
B2b
Founded
2003
Raised
$23.8M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
€20,000,000
Post-IPO debt - 2017
$1,300,000
Grant - 2014
Team Size
10+
Employees
Location
Headquarters
€20,000,000 Post-IPO debt
The Times of Israel

BiondVax gets €20 million loan for universal flu vaccine

NoCamels - Israeli Tech and Innovation News

Israel’s BiondVax Moves Closer To Universal Flu Vaccine

Health Science
NoCamels - Israeli Tech and Innovation News

BiondVax's Flu Vaccine Trial Recruitment Complete

Health